About Image


      Bone Biologics is a publicly traded company based in Burlington, MA and is focused on developing and marketing orthobiologic products. Our proprietary platform technology is NELL-1, a recombinant human protein growth factor that is essential for normal bone development. Our lead product is a NELL-1 based bone graft substitute for spine fusion, targeting the rapidly growing orthobiologics market. Our goal is to offer patients superior safety with uncompromising efficacy relative to existing technologies. NELL-1  provides specific targeted regulation over bone regeneration in the presence of targeted osteogenic cells, as both demonstrated in the lab and through the use of animal testing, unlike any other current therapy. It has been shown not to form bone when applied to non-osteogenic cells such as myoblasts (a type of embryonic progenitor cell that differentiates to give rise to muscle cells) nor does it induce adipogenesis (the formation of fat that can occur within the bone matrix often exhibited as cysts) that results in weaker bone.

      Our mission is to utilize the power of NELL-1 to improve clinical outcomes and reduce total health care delivery costs associated with spinal fusion. Bone Biologics is focused on bone repair and regeneration applications and is committed to exploring additional applications of the NELL-1 technology to enhance bone regeneration and repair in areas where the current options provide suboptimal patient outcomes.


      Leadership Image


          The Bone Biologics leadership team consists of some of the top leaders and innovators of orthobiologics in regenerative medicine. Not only does our leadership provide strategic oversight of the Company, they contribute to the collective advancement of the industry. This leadership is instrumental in fulfilling our mission to improve clinical outcomes and reduce health care delivery costs associated with lumbar spinal fusion.


          Products Image


              While Bone Biologics has chosen to focus its initial product development efforts in spinal fusion, we believe that this regenerative medicine technology has potential in the broader fields of bone regeneration and repair including osteoporosis, chondrocytes and applications using mesenchymal stem cells.


              Investor Relations

              Investor Relations Image

              Press Releases

              Current Press Releases

              News Archive

              New Strategy Aims to Enhance Efficacy and Safety of Bone Repair Treatment

              PHILADELPHIA, (January 6, 2016) – Bone morphogenetic protein-2 (BMP2) is used clinically to promote bone repair. However, the high BMP2 concentrations required to stimulate bone growth in humans may produce life-threatening adverse effects such as cervical swelling in spinal fusion procedures, a problem that prompted an FDA warning in 2008. Now, a team of clinicians and engineers has shown that adding the protein kinase C-binding protein NELL-1 (Nel-like molecule-1) to BMP2 therapy may allow clinicians to achieve better results at lower – and safer – BMP2 doses. Their findings are reported in The American Journal of Pathology.

              + Read More

              Bone Biologics Corporation Appoints New CEO and COO

              EDISON, N.J., Aug. 13, 2015 — Bone Biologics Corporation, (“Bone Biologics” or “The Company”) announced today the appointment of Mr. Stephen R. La Neve as the Company’s Chief Executive Officer and President, and Mr. Jeffrey Frelick as the Company’s Chief Operating Officer, each to be effective on August 17, 2015. Mr. La Neve replaces our interim Chief Executive Officer, Michael Schuler.

              + Read More

              Bone Biologics Corp Completes Financing With Hankey Capital, LLC

              EDISON, N.J., May 6, 2015 — Bone Biologics, Corp., (“Bone Biologics”) announced today the completion of a $2M funding round with Hankey Capital, LLC (“Hankey Capital”) of Los Angeles, CA. The company is developing a proprietary protein for use in bone regenerative medicine using the patented recombinant human protein known as UCB-1 (or NELL-1) for use with patients undergoing spinal fusion.

              + Read More

              Bone Biologics Corp Completes Merger with AFH Acquisition X, Inc

              Edison, NJ, October 16, 2014– Bone Biologics, Corp., (“Bone Biologics” or “The Company”) a company developing a proprietary protein for use in bone regenerative medicine using the patented recombinant human protein known as UCB-1 (or NELL-1™) for use with patients undergoing spinal fusion, announced today the completion of a reverse merger of privately held Bone Biologics, Inc.  and AFH Acquisition X, Inc, a fully-reporting company with the Securities and Exchange Commission. Upon completion of the merger, the combined company changed its name to Bone Biologics, Corp and anticipates that trading in the Company’s common stock will commence on the OTC Bulletin Board following regulatory approvals.

              + Read More

              « Newer EntriesOlder Entries »


              Contact Image


                  General Inquiries:
                  Chris Martin
                  412.749.9299 x2

                  Investor Inquiries:
                  Mark Collinson

                  Media Inquiries:
                  Tracy Williams
                  310.824.9000 x22

                  For information regarding our company and/or products, please complete the form below.

                  Your Name (required)



                  Email (required)


                  Preferred Means of Reply

                  Your Message

                  Scratch Pad
                  Parent : investor-relations 11